Salivary progesterone and estriol among pregnant women treated with 17-⍺-hydroxyprogesterone caproate or placebo - 21/08/11
National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network
Résumé |
Objective |
The objectives of the study was to determine whether salivary progesterone (P) or estriol (E3) concentration at 16-20 weeks' gestation predicts preterm birth or the response to 17⍺-hydroxyprogesterone caproate (17OHPC) and whether 17OHPC treatment affected the trajectory of salivary P and E3 as pregnancy progressed.
Study Design |
This was a secondary analysis of a clinical trial of 17OHPC to prevent preterm birth. Baseline saliva was assayed for P and E3. Weekly salivary samples were obtained from 40 women who received 17OHPC and 40 who received placebo in a multicenter randomized trial of 17OHPC to prevent recurrent preterm delivery.
Results |
Both low and high baseline saliva P and E3 were associated with a slightly increased risk of preterm birth. However, 17OHPC prevented preterm birth comparably, regardless of baseline salivary hormone concentrations. 17OHPC did not alter the trajectory of salivary P over pregnancy, but it significantly blunted the rise in salivary E3 as well as the rise in the E3/P ratio.
Conclusion |
17OHPC flattened the trajectory of E3 in the second half of pregnancy, suggesting that the drug influences the fetoplacental unit.
Le texte complet de cet article est disponible en PDF.Key words : 17-alpha-hydroxyprogesterone caproate, longitudinal studies, preterm birth, salivary estriol, salivary progesterone
Plan
Cite this article as: Klebanoff MA, Meis PJ, Dombrowski MP, et al. Salivary progesterone and estriol among pregnant women treated with 17-⍺-hydroxyprogesterone caproate or placebo. Am J Obstet Gynecol 2008;199:506.e1-506.e7. |
|
Reprints not available from the authors. |
|
Supported by Grants HD27860, HD36801, HD27917, HD21414, HD27861, HD27869, HD27905, HD34208, HD34116, HD21410, HD27915, HD34136, HD34210, HD34122, HD40500, HD40544, HD34116, HD40560, and HD40512 from the National Institute of Child Health and Human Development. |
Vol 199 - N° 5
P. null - novembre 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?